Design and analysis of unit cost estimation studies: How many hospital diagnoses? How many countries?

Health Economics

Volumn 12, Issue 7, 2003, Pages 517-527

  Glick, Henry A ^a   Orzol, Seam M ^a   Tooley, Joseph F ^c   Polsky, Daniel ^a   Mauskopf, Josephine O ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b RTI INTERNATIONAL   (United States)

^c NONE

Author keywords

Cost effectiveness; Costs; Economics; Generalizability

Indexed keywords

ANALYTICAL ERROR; ARITHMETIC; ARTICLE; BELGIUM; CLINICAL STUDY; CONTROLLED STUDY; COST UTILITY ANALYSIS; DIAGNOSIS; FRANCE; HEALTH ECONOMICS; HOSPITAL COST; LENGTH OF STAY; MEDICARE; PRIORITY JOURNAL; SPAIN; WESTERN EUROPE;

COSTS AND COST ANALYSIS; DIAGNOSIS-RELATED GROUPS; EUROPE; HEALTH SERVICES RESEARCH; HOSPITAL COSTS; HOSPITAL UNITS; HUMANS; MEDICARE; MODELS, ECONOMETRIC; UNITED STATES;

EID: 0038049687     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.750     Document Type: Article

References (18)

1. Legendre C, Norman D, Keating M, Maclaine G, Grant D. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. Transplantation 2000; 70: 1463-1468.
2. Glick H, Willke R, Polsky D et al. Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. Economic evaluation of a phase III clinical trial in Europe and Australia. Int J Technol Assess Health Care 1998; 14: 145-160.
3. Schulman KA, Dorsainvil D, Yabroff KR et al. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone-marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21: 607-614.
4. Mark DB, Hlatky MA, Califf RM et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-1424.
5. Mauskopf J, Cates S, Griffin A, Neighbors D, Lamb S, Rutherford C. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics 2000; 17: 611-620.
6. Markowitz M, Mauskopf J, Halpern M. Cost-effectiveness model of adjunctive lamotrogine for the treatment of epilepsy. Neurology 1998; 51: 1026-1033.
7. Riviere M, Wang S, Leclerc C, Fitzsimon C, Tretiak R. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. CMAJ 1997; 156: 991-997.
8. Johannesson M, Jonsson B, Kjekshus J, Olsson A, Pederson T, Wede H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin study group. N Engl J Med 1997; 336: 332-336.
9. Glick H, Cook J, Kinosian B et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the studies of left ventricular dysfunction (SOLVD) Treatment Trial. J Cardiac Fail 1995; 1: 371-380.
10. Mauskopf J, Richter A, Annemans L, Maclaine G. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice. Pharmacoeconomics 2000; 18: 239-251.
11. Schulman KA, Buxton M, Glick H et al. Results of the economic evaluation of the FIRST study: a multinational prospective economic evaluation. Int J Technol Assess Health Care 1996; 12: 698-713.
12. Glick HA, Orzol SM, Tooley JF, Remme WJ, Sasayama S, Pitt B. Economic evaluation of the Randomized Aldactone Evaluation Study (RALES): treatment of patients with severe heart failure. Cardiovasc Drugs Therapy (in press).
13. Goeree R, Gafni A, Hannah M, Myhr T, Blackhouse G. Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference? Pharmacoeconomics 1999; 15: 561-572.
14. Rules and regulations. Federal Register 2000; 65(47): 160-169.
15. DRG Guide 2000. Medicode, Inc., Salt Lake City, UT, 1999.
16. Office of Economic Cooperation and Development. OECD Health Data 1998. OECD Electronic Publications: Paris, 1998.
17. Schulman K, Burke J, Drummond M et al. Resource costing for multinational neurological clinical trials: methodology and results. Health Econ 1998; 7: 629-638.
18. Health Care Financing Administration. Medicare programs: Revisions to payment policies and adjustments to the relative value units under the physician-fee schedule for calendar year 1996. Federal Register 1995; 60.